TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $486,005 | -48.9% | 54,363 | -12.2% | 0.00% | -33.3% |
| Q2 2023 | $951,506 | -12.1% | 61,947 | +28.7% | 0.00% | 0.0% |
| Q1 2023 | $1,082,106 | -2.0% | 48,115 | -8.3% | 0.00% | -25.0% |
| Q4 2022 | $1,103,654 | -19.7% | 52,480 | -5.9% | 0.00% | 0.0% |
| Q3 2022 | $1,374,000 | -4.0% | 55,770 | -5.5% | 0.00% | 0.0% |
| Q2 2022 | $1,431,000 | -29.7% | 59,040 | -25.3% | 0.00% | 0.0% |
| Q1 2022 | $2,036,000 | -4.4% | 79,000 | +15.2% | 0.00% | 0.0% |
| Q4 2021 | $2,129,000 | +27.9% | 68,600 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $1,664,000 | +66.2% | 68,600 | 0.0% | 0.00% | +50.0% |
| Q2 2021 | $1,001,000 | -41.6% | 68,600 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $1,713,000 | -8.4% | 68,600 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,870,000 | – | 68,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |